- Home
- CVKD vs ABP Comparison
CVKD vs ABP Comparison
Compare CVKD & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- ABP
- Stock Information
- Founded
- CVKD 2022
- ABP 2004
- Country
- CVKD United States
- ABP United States
- Employees
- CVKD N/A
- ABP 6
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- ABP Health Care
- Exchange
- CVKD Nasdaq
- ABP Nasdaq
- Market Cap
- CVKD 31.5M
- ABP 12.1M
- IPO Year
- CVKD 2023
- ABP N/A
- Fundamental
- Price
- CVKD $16.80
- ABP $0.32
- Analyst Decision
- CVKD Strong Buy
- ABP Strong Buy
- Analyst Count
- CVKD 1
- ABP 1
- Target Price
- CVKD $32.00
- ABP $4.00
- AVG Volume (30 Days)
- CVKD 20.0K
- ABP 223.3K
- Earning Date
- CVKD 05-08-2025
- ABP 05-18-2025
- Dividend Yield
- CVKD N/A
- ABP N/A
- EPS Growth
- CVKD N/A
- ABP N/A
- EPS
- CVKD N/A
- ABP N/A
- Revenue
- CVKD N/A
- ABP $183,000.00
- Revenue This Year
- CVKD N/A
- ABP N/A
- Revenue Next Year
- CVKD N/A
- ABP N/A
- P/E Ratio
- CVKD N/A
- ABP N/A
- Revenue Growth
- CVKD N/A
- ABP 50.00
- 52 Week Low
- CVKD $5.70
- ABP $0.23
- 52 Week High
- CVKD $22.90
- ABP $13.00
- Technical
- Relative Strength Index (RSI)
- CVKD 49.81
- ABP N/A
- Support Level
- CVKD $15.85
- ABP N/A
- Resistance Level
- CVKD $17.33
- ABP N/A
- Average True Range (ATR)
- CVKD 1.31
- ABP 0.00
- MACD
- CVKD 0.21
- ABP 0.00
- Stochastic Oscillator
- CVKD 82.32
- ABP 0.00
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.